And that was before we had a taste of Top-Line results for the P2b Brilacidin trial.
The last Aspire deal added 25% to pps -starbuxsux
Yes, indeed it did.
The positive P2b results means in a addition to the trials already planned for Brilacidin-OM, Prurisol 2/3, and Kevetrin combination, there will be a Phase 3 clinical trial for Brilacidin ABSSSI.
Some funds will have to be raised to fund all these trials. Especially if CTIX goes the Brilacidin Phase 3 alone.
Funds will also be needed to fund current trials, research, and possibly to prepare for uplisting requirements. Shares are needed for compensation of new Board Members.
Alternatively, CTIX could partner or sell off Brilacidin, and thus not need the S3. But that is also a form of dilution, of assets as opposed to shares. If there are negotiations, CTIX will have a stronger hand by showing they have the funds, or funding ability, in place to go it alone.
Another alternative is a partnership agreement in which the partner was able to buy enough shares to be an affiliate, with a board of directors presence.
Still another alternative is another Aspire round of financing. The difference being only that the shares are already registered.
So combine them all together, and Cellceutix needs some shares on the shelf. If, how and when they are used could be very variable. With additional news catalsyst in the hopper, and they could end us being used at a higher share price.
Substantial offerings do tend to pull the share price to the offering price. But... we don't know when, if, and at what share price CTIX may be with so many catalsyst in the short term. So sure, the share price could pull back, but from what price? $3.30? $5.50?
It would be difficult to prove that was the cause...temporal sequentiality is only one part of the causality equation.
All in all, I think the Aspire deals were good for where the company stood at the time. Having 75 million ready and waiting is what the company needs now. Like I said, new phase for CTIX all around.
Market Data 
Markets 
AI
